News center
Building Foundations
From Standards to Synergy
The summit opened with remarks from SDM Chairman Mr.Cao Tiejun. Reflecting on two decades of company growth and industry trends, he stressed the strategic need to tightly integrate project management with personnel development. “Seamless collaboration directly impacts project quality and client value,” he noted. “We must break down barriers and synchronize our expertise with efficiency.” This set a practical, action- oriented tone for the days ahead.
◉ Setting Clear Standards: Making Processes Actionable
In a deep-dive session on the Project Management Handbook, PMD leads used a module-by-module approach with live Q&A to connect procedures with real-world scenarios, transforming guidelines into practical collaboration checklists.
CRM leads then walked through the CRM Handbook, creating a support system aimed at role-fit and skill development - ensuring project execution and team capacity work in sync.
Driving Solutions
From Dialogue to Cross-Functional Flow
◉ Walking in Each Other’s Shoes: Smoothing PM-CRM Collaboration
A highlight was the workshop on Bridging Gaps in Project Management and Operations. Facilitated by senior leads, representatives from all departments engaged in root-cause analysis and joint solutioning around common challenges like handoff delays, communication lags, and slow issue escalation-resulting in concrete, actionable alignment strategies.
◉ Close-Loop Problem Solving: From Issues to Action Plans
Discussions expanded to cross-functional support—covering project safeguards from data and finance standpoints, and mapping synergy across CRC collaboration, collaboration with Medical Affairs, and technical support. SDM’s senior leadership, including Chairman Cao Tiejun and Deputy GM Song Hong, participated throughout, emphasizing the need to “break down departmental silos and make every link a point of collaborative strength.
From Alignment to Action
Charting the Course Ahead
KY-0301 is the world's first nano-dual-anti-ADC developed by Novatim based on its own innovative nano-dual-anti-ADC platform “TPEBEN”.
Beijing Shouyan Lab is certified by NGSP in the United States.
Provide diverse and better treatment options for patients worldwide.
At the intersection of the end of the year, we sincerely invite you to join us in focusing on the shining points of the year, and to look back together and cherish the bright moments that have illuminated our way forward in the past year.
On October 24-25 2024, Dr. Yuwen, CBO and SVP of SDM Bioservices, was invited to attend the 2024 International Biomedical Industry Innovation Beijing Forum co-sponsored by DIA and Beijing Advanced Medical Equipment Industry Innovation Alliance. The forum brings together representatives of global regulators, leading experts in biomedicine, industry leaders and academics to discuss the latest trends and industry innovations in global drug development.
AMWC China 2024 World Congress on Aesthetics and Anti-Aging was successfully carried out in Chengdu on October 18-20, 2024, with medical and aesthetic experts, scholars, and industry practitioners from all over the world participating and presenting their latest achievements.
On July 24, SDM Bioserices and Australia JP Medical Consulting Pty Ltd (hereinafter referred to as "JP Medical Consulting") announced a strategic cooperation. The cooperation aims to make full use of the clinical resources and professional advantages of the two sides in the field of medicine in China and Australia, promote the internationalization of clinical trials and new drug research and development, and provide one-stop services for Chinese biopharmaceutical enterprises in Australian clinical trials.
August 1, China, Beijing, Liu Xueliang, deputy secretary of the District Party Committee and district governor, led a team to visit key enterprises of Daxing biomedical Industry Base to investigate the development and construction of pharmaceutical research and development service platform enterprises.
On the way to further explore and promote the professional development of medical clinical trials, SDM and Tonghua Dongbao jointly successfully held a nine-month "Diabetes Professional CRA Series course".
On July 11-12, 2024, MedDRA MSSO successfully held the fourth offline face-to-face training of 2024 at the Shenyang office of SDM. As the organizer of this event, SM gathered together with more than 40 experts from various fields such as CRO, pharmaceutical companies and partners, including medical coders, data management and statistics, drug safety/pharmacovigilance, medical writers and other modules.
On July 3, 2024, SDM Bioservices and Shanghai Ruiningkang Bio-Pharmaceutical Technology Development Co., LTD. (" Ruiningkang Bio ") reached a strategic cooperation to work together to help innovative drugs in the quantitative pharmacology, dose exploration level, and promote more innovative drugs with global competitiveness to the market.
On November 21, 2023, Beijing Kangle Guard Biotechnology Co., Ltd. is affiliated with Muhammadiyah University Malang, Indonesia (at) to start the "restructuring nine price 6/11/16/18/31/33/45/52/58) human papilloma virus (HPV) vaccine (e. coli) phase III clinical trials into the group of vaccination. As a CRO focused on vaccine clinical trials, Shanghai SDM undertook the phase III clinical study of the vaccine project in Indonesia, responsible for project management, data management, biostatistical analysis, pharmacovigilance and other important work of the project.
The laboratories operated by SDM in the North and South have their own specialties and technical advantages. Among them, Beijing Shouyan, with several P2 and P2+ laboratories and complete PCR testing facilities, is one of the few testing organizations in China focusing on bioanalysis of vaccines and traditional Chinese medicines; Hangzhou Amador focuses on XDC, macromolecules, and CGT, etc., and provides one-stop bioanalytical services for ADC drugs, which is a technological leader in the industry.
Meiji has advanced its oral paclitaxel softgel capsule, MJC-001, to clinical trial stage. With support from SDM Bioservices, Meiji received FDA clearance for its Investigational New Drug (IND) application, positioning it among the leading developers of oral paclitaxel formulations.
Listen to Dr. Liping Shen: Innovating Vaccine Bioanalysis for Change
KY-001 is an oral small-molecule inhibitor targeting the YAP/TAZ-TEAD interaction in the Hippo pathway with a proposed indication for advanced solid tumors driven by Hippo dysregulation.
Dr. Wang delivered a keynote presentation titled "The Power of Quantitative Pharmacology: Critical Insights from Landmark Clinical Development and Regulatory Cases," providing an in-depth analysis of the central role of quantitative pharmacology across the entire clinical development lifecycle of investigational drugs.
The seminar attracted representatives from nearly 30 pharmaceutical companies in the Sichuan-Chongqing region, injecting new momentum into the regional biopharmaceutical innovation ecosystem.
On September 6-7, 2025, SDM’s Clinical Operations and SMO teams come together at the 21st Century Tower in Beijing for an alignment workshop. Focused on “unifying our approach and enhancing collaboration,” the two-day event tackled key integration points between project and talent management. Through focused discussions, we turned consensus into actionable plans, established standardized workflows, and built cross-functional synergy-all strengthening SDM’s foundation to position SDM a higher-quality CRO to better serve clients and patients.
As BaoPharm's strategic regulatory partner, SDM Bioservices' global registration team delivered comprehensive support for this project, including gap analysis, technical dossier compilation, and submission management services.
As a clinical development pioneer with twenty years of China-focused expertise, SDM Bioservices provides comprehensive clinical research solutions to pharmaceutical partners worldwide. Our integrated capabilities include proven regulatory submission experience across China, U.S. and EU markets, innovative early-phase development approaches, reliable bioanalytical services, and demonstrated expertise in managing large-scale clinical trials for therapeutic drugs, and specialized knowledge in vaccines and medical aesthetics.
Get in touch with SDM experts for your questions or comments and a member of our team will get back to you directly.
Let's Start a Conversation
